Published in Lancet on June 13, 1992
Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A (1992) 4.58
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A (1996) 3.29
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer (2009) 3.06
Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A (1996) 2.10
Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. J Virol (1996) 2.03
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98
Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol (1996) 1.33
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol (1995) 1.25
The 131-amino-acid repeat region of the essential 39-kilodalton core protein of fowlpox virus FP9, equivalent to vaccinia virus A4L protein, is nonessential and highly immunogenic. J Virol (1998) 1.14
Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol (1994) 1.12
p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci U S A (1996) 1.11
Effect of Corticosteroids on RVNA production of a patient with acute disseminated encephalomyelitis following rabies vaccination as well as administration of HRIG. Hum Vaccin Immunother (2014) 1.06
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol (1993) 1.01
Non-replicating expression vectors: applications in vaccine development and gene therapy. Epidemiol Infect (1996) 0.92
Enteric immunization of mice against influenza with recombinant vaccinia. Proc Natl Acad Sci U S A (1994) 0.89
The present and future of rabies vaccine in animals. Clin Exp Vaccine Res (2013) 0.88
The next wave of recombinant and synthetic anticancer vaccines. Semin Cancer Biol (1995) 0.85
A selectable and excisable marker system for the rapid creation of recombinant poxviruses. PLoS One (2011) 0.82
Developments in rabies vaccines. Clin Exp Immunol (2012) 0.77
The Jenner bicentenary; still uses for smallpox vaccine. Epidemiol Infect (1996) 0.75
Canarypox virus as a vaccine vector. Lancet (1992) 0.75
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
The complete DNA sequence of vaccinia virus. Virology (1990) 7.76
Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A (1982) 7.04
Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature (1979) 6.76
Behavioral disinhibition and the development of substance-use disorders: findings from the Minnesota Twin Family Study. Dev Psychopathol (1999) 5.90
RNA polymerase activity in purified infectious vaccinia virus. Proc Natl Acad Sci U S A (1967) 5.49
Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen. J Virol (1989) 5.48
Diagnosis and management of aortic dissection. Eur Heart J (2001) 5.39
Structure and replication of the genome of the hepatitis delta virus. Proc Natl Acad Sci U S A (1986) 5.23
An investigation of traveller's diarrhoea. Lancet (1970) 4.99
Molecular cloning of hepatitis delta virus RNA from an infected woodchuck liver: sequence, structure, and applications. J Virol (1988) 4.96
Antigenomic RNA of human hepatitis delta virus can undergo self-cleavage. J Virol (1988) 4.59
Herpes simplex virus 1 mutant deleted in the alpha 22 gene: growth and gene expression in permissive and restrictive cells and establishment of latency in mice. J Virol (1985) 4.17
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11
A specific base transition occurs on replicating hepatitis delta virus RNA. J Virol (1990) 4.05
Characterization of self-cleaving RNA sequences on the genome and antigenome of human hepatitis delta virus. J Virol (1988) 4.05
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med (1994) 3.72
Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J Biol Chem (1975) 3.66
Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A (1984) 3.58
Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication. J Virol (1990) 3.57
Inhibition of interferon action by actinomycin. Biochem Biophys Res Commun (1964) 3.55
Growth characteristics of cytomegalovirus in human fibroblasts with demonstration of protein synthesis early in viral replication. J Virol (1973) 3.48
NYVAC: a highly attenuated strain of vaccinia virus. Virology (1992) 3.38
A study of Escherichia coli isolated from chronic urinary infection. J Med Microbiol (1969) 3.32
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
Electrophoresis of thymidine kinase activity synthesized by cells transformed by herpes simplex virus. Virology (1972) 3.05
Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A (1982) 3.01
Template switching by reverse transcriptase during DNA synthesis. J Virol (1990) 2.98
Using nurses for preventive activities with computer assisted follow up: a randomised controlled trial. BMJ (1989) 2.95
Comparison of cromoglycate (cromolyn) and theophylline in controlling symptoms of chronic asthma. A collaborative study. Lancet (1977) 2.90
Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res (2001) 2.90
Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation (2009) 2.85
Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1983) 2.79
Immunization against Diphtheria with Alum-precipitated Toxoid-II. Br Med J (1942) 2.77
Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol (1981) 2.74
Psychotic illness following 'mabi bark tea' consumption. Br J Psychiatry (1992) 2.72
The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J (2004) 2.63
Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. Virology (1991) 2.63
Comparison of influenza serological techniques by international collaborative study. Vaccine (1994) 2.55
Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene. J Virol (1995) 2.55
Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci U S A (1997) 2.54
MutS mediates heteroduplex loop formation by a translocation mechanism. EMBO J (1997) 2.52
A homeodomain protein related to caudal regulates intestine-specific gene transcription. Mol Cell Biol (1994) 2.42
Transient Induction of Phenylalanine Ammonia-Lyase and 4-Coumarate: CoA Ligase mRNAs in Potato Leaves Infected with Virulent or Avirulent Races of Phytophthora infestans. Plant Physiol (1987) 2.36
Replication of human hepatitis delta virus in primary cultures of woodchuck hepatocytes. J Virol (1987) 2.36
Assembly of hepatitis delta virus particles. J Virol (1992) 2.36
Nucleotide phosphohydrolase in purified vaccinia virus. J Virol (1968) 2.35
Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med (2000) 2.33
Structural asymmetries in the human brain: a voxel-based statistical analysis of 142 MRI scans. Cereb Cortex (2001) 2.32
Protein kinase and specific phosphate acceptor proteins associated with vaccinia virus cores. J Virol (1972) 2.22
Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology (1991) 2.17
Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology (1992) 2.15
Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A (1996) 2.10
Modification of the 5'-terminus of mRNA by soluble guanylyl and methyl transferases from vaccinia virus. Proc Natl Acad Sci U S A (1975) 2.10
Rapid immune response to influenza vaccination. Lancet (1993) 2.09
Roles of estrogen receptor-alpha gene expression in reproduction-related behaviors in female mice. Endocrinology (1998) 2.05
Phylogenetic aspects of C-reactive protein and related proteins. Ann N Y Acad Sci (1982) 2.03
Hepatitis delta virus genome replication: a polyadenylated mRNA for delta antigen. J Virol (1990) 2.03
Vaccinia virus host range genes. Virology (1990) 2.02
HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med (1995) 1.99
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98
Hereditary haemorrhagic telangiectasia, an Australian cohort: clinical and investigative features. Intern Med J (2014) 1.98
Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med (1991) 1.97
An update on the vaccinia virus genome. Virology (1993) 1.95
Reverse transcriptase of human immunodeficiency virus type 1: functionality of subunits of the heterodimer in DNA synthesis. J Virol (1992) 1.94
Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg (1998) 1.91
Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther (1992) 1.88
Summary of a workshop on new and useful methods in viral diagnosis. J Infect Dis (1978) 1.87
Rapid detection of human cytomegalovirus in the urine of humans. J Infect Dis (1985) 1.85
Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol (1989) 1.84
The stability and properties of bimolecular lipid leaflets in aqueous solutions. J Theor Biol (1963) 1.80
TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc Natl Acad Sci U S A (1994) 1.80
Self-ligating RNA sequences on the antigenome of human hepatitis delta virus. J Virol (1989) 1.78
Ketamine sedation for children in the emergency department. Emerg Med (Fremantle) (2001) 1.78
Polyadenylate polymerase from vaccinia virions. Nat New Biol (1973) 1.76
Two nucleic acid-dependent nucleoside triphosphate phosphohydrolases from vaccinia virus. Nucleotide substrate and polynucleotide cofactor specificities. J Biol Chem (1974) 1.76
Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology (1992) 1.76
Cloned hepatitis delta virus cDNA is infectious in the chimpanzee. J Virol (1989) 1.75
Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail (1999) 1.75
A randomized controlled trial comparing oxytocin administration before and after placental delivery in the prevention of postpartum hemorrhage. Am J Obstet Gynecol (2001) 1.73
A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med (1991) 1.73
Outbreak of infantile gastro-enteritis caused by Escherichia coli O114. Arch Dis Child (1970) 1.71
The antigen of hepatitis delta virus: examination of in vitro RNA-binding specificity. J Virol (1991) 1.70
Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology (1982) 1.67
Outbreak of poliomyelitis-like paralysis associated with enterovirus 71. Pediatr Infect Dis J (1989) 1.67
Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine (1991) 1.66
Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study. Neurology (2010) 1.66
Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med (1999) 1.65
Factors associated with early failure of arteriovenous fistulae for haemodialysis access. Eur J Vasc Endovasc Surg (1996) 1.65
Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol (2001) 1.64
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis (1999) 1.64